» Articles » PMID: 34158417

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review

Overview
Date 2021 Jun 23
PMID 34158417
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is an inflammatory disease of central nervous system (CNS). The mmune system plays an important role in its pathogenesis. Current treatments are unable to cure patients and prevent the progression of MS lesions. Stem cell-based cell therapy has opened a new window for MS treatment. Stem cells regulate immune responses and improve axonal remyelination. Stem cells can be obtained from different origins such as embryonic, neural, bone marrow, and adipose tissues. But yet there is a challenge for the selection of the best cell source for stem cell therapy. Mesenchymal stem cells (MSCs) are a type of stem cell obtained from different origins and have significant immunomodulatory effects on the immune system. The increasing evidence have suggested that umbilical cord and adipose tissue can be a suitable source for isolation of MSCs. Moreover, human amniotic epithelial cells (hAECs) as novel stem cell origins by having immunoregulatory effects, regenerative effects, and less capacity of antigenicity can be a candidate for MS treatment. This review discussed the mechanistic effects of MSCs with a focus on human amniotic epithelial cells, which can be used to treatment and improvement of outcome in MS disease.

Citing Articles

Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.

Sheikhi K, Ghaderi S, Firouzi H, Rahimibarghani S, Shabani E, Afkhami H Front Cell Dev Biol. 2025; 13:1517369.

PMID: 39963155 PMC: 11830822. DOI: 10.3389/fcell.2025.1517369.


Local fistula injection of allogeneic human amnion epithelial cells is safe and well tolerated in patients with refractory complex perianal Crohn's disease: a phase I open label study with long-term follow up.

Keung C, Nguyen T, Lim R, Gerstenmaier A, Sievert W, Moore G EBioMedicine. 2023; 98:104879.

PMID: 38042747 PMC: 10755113. DOI: 10.1016/j.ebiom.2023.104879.


Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.

Hosseinalizadeh H, Rabiee F, Eghbalifard N, Rajabi H, Klionsky D, Rezaee A Front Med (Lausanne). 2023; 10:1244298.

PMID: 37828948 PMC: 10565010. DOI: 10.3389/fmed.2023.1244298.


Sertoli Cell-Conditioned Medium Induces Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells to Male Germ-Like Cells in Busulfan-Induced Azoospermic Mouse Model.

Khanmohammadi N, Malek F, Takzaree N, Malekzadeh M, Khanehzad M, Akanji O Reprod Sci. 2023; 31(2):375-392.

PMID: 37737972 DOI: 10.1007/s43032-023-01332-7.


Activating transcription factor-2 supports the antioxidant capacity and ability of human mesenchymal stem cells to prevent asthmatic airway inflammation.

Ju H, Yun H, Kim Y, Nam Y, Lee S, Lee J Exp Mol Med. 2023; 55(2):413-425.

PMID: 36765266 PMC: 9981582. DOI: 10.1038/s12276-023-00943-z.


References
1.
Yang H, Sun J, Wang F, Li Y, Bi J, Qu T . Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study. Oncotarget. 2016; 7(45):72537-72545. PMC: 5341927. DOI: 10.18632/oncotarget.12345. View

2.
Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar H . Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 1995; 38(5):788-96. DOI: 10.1002/ana.410380514. View

3.
Jafarzadeh Bejargafshe M, Hedayati M, Zahabiasli S, Tahmasbpour E, Rahmanzadeh S, Nejad-Moghaddam A . Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis. Stem Cell Investig. 2020; 6:44. PMC: 6987330. DOI: 10.21037/sci.2019.10.06. View

4.
Staff N, Madigan N, Morris J, Jentoft M, Sorenson E, Butler G . Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016; 87(21):2230-2234. PMC: 5123559. DOI: 10.1212/WNL.0000000000003359. View

5.
Mazini L, Rochette L, Amine M, Malka G . Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019; 20(10). PMC: 6566837. DOI: 10.3390/ijms20102523. View